Tue, Oct 21, 2014, 2:24 AM EDT - U.S. Markets open in 7 hrs 6 mins

Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

hbomb57108 11 posts  |  Last Activity: Aug 29, 2014 9:46 AM Member since: Mar 26, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • hbomb57108 hbomb57108 Aug 29, 2014 9:46 AM Flag

    Technically speaking, GSK gets a 3% royalty.

  • Reply to

    Twitter comment on comet

    by marinolman11 Aug 10, 2014 3:01 PM
    hbomb57108 hbomb57108 Aug 11, 2014 4:46 PM Flag

    "I have no special insight into the DSMB's instructions, but I'm assuming that there was a delay for data cleaning before the March 24 announcement, so I'm guessing the actual interim trigger occurred in Jan/Feb. I would expect a similar delay period following the final analysis trigger."

    Thanks, I had wondered your rationale for some time. That pretty much explains it. I would be shocked if blended median OS was above 10 months. I have yet to see 3rd line active drug result in anything greater than 7.8 months.(mostly low 7's) Unless I am overlooking something such as liver mets exclusion. COMET 2 will be one hellacious population. (greater than 5 pain score 3rd line treatment)

    I am really intrigued to compare OS HR's from COMET 1 and 2. I think that would allow us to see how truly difficult it may be to treat these later staged patients. It may be very difficult to get an approved drug in this 3rd line space.-----Still in camp that believes odds are Cabo demonstrates stat sig in COMET 1, but I'm certainly crossing my fingers.

  • Reply to

    Melanoma CME covers recent ASCO data

    by wilderguide Aug 10, 2014 2:08 PM
    hbomb57108 hbomb57108 Aug 10, 2014 9:25 PM Flag

    I haven't looked at the presentation yet, keep in mind Zelboraf had 100% metabolic response rate by itself in 24 patient phase 1 study. The early phase 1B Cobi/Zelboraf also had 100% metabolic response rate. Metabolic response rate by PET criteria is much easier to attain than Recist. CT Recist response can be masked by structural scarring. Regardless, I think Cobi/Zelboraf 87% Recist response rate is the most impressive data set in treatment naïve setting compared to 50-60's with GSK combo or monotherapy Zelboraf.

  • Reply to

    Twitter comment on comet

    by marinolman11 Aug 10, 2014 3:01 PM
    hbomb57108 hbomb57108 Aug 10, 2014 8:31 PM Flag

    " I am very confident we are overdue. What the tweeter ignores is that we have a hard data point in that the result of the interim analysis was reported in late March, over 4 months ago. The cutoff for that analysis was 387 events. If we assume a blended median OS of 10 months, that would imply an average event rate of 48 per month. The final trigger is based on an additional 191 events."

    If we assume 4-8 week data lock that puts us at late August/September for topline results under your 48 per month event rate.

  • Reply to

    Cabo vs Vandetinib, Sunitinib and Sorafinib

    by erniewerner Aug 3, 2014 1:29 PM
    hbomb57108 hbomb57108 Aug 5, 2014 8:01 AM Flag

    "Additionally, there is a CRADA trial comparing Cabo to frontline sorafinib in HCC."

    That was in the original plans, but it got scraped. The frontline RCC comparing to Sutent is ongoing.

  • hbomb57108 hbomb57108 Aug 2, 2014 12:43 PM Flag

    "Of course, but a failure of COMET-1 would also be doubly painful since neither revenues nor financing would be as good."

    No argument from me here. COMET-1 is awfully important. I really don't want to know how Exelixis would recover financially. Makes me wonder about the covenants. Can Exelixis run near cash depletion past METEOR results? It could be that Exel is banking on positive results in METEOR if COMET-1 doesn't come through. The other alternative could be a sale to Roche upon unsuccessful COMET-1, which isn't a pleasant alternative.

  • From slide on Exel earnings conference call

    "Two randomized phase 2 ISTs have reached full enrollment
    15
    •? Eastern Cooperative Oncology Group (ECOG) trial in 2
    line
    EGFR wild type NSCLC: cabozantinib vs. erlotinib vs. cabozantinib +
    erlotinib
    •? Gynecologic Oncology Group (GOG) trial in platinum resistant/
    refractory ovarian cancer patients: cabozantinib vs.weekly paclitaxel
    •? Both studies expecting data late 2014/early 2015"

    It was also stated that existing financial runway will put them past METEOR readout.

    With guidance above $200 million for end of year, that puts METEOR readout in 3rd quarter 2015 at the latest. I wouldn't be surprised to see full enrollment from METEOR in next 2 months. 204 of 211 sites are actively recruiting in METEOR according to the site.

    With approx. $75 million burn per quarter, we are getting awfully close to another financing. Typically Exel likes to raise cash with 1 year runway. As of now, I take management's not raising cash before COMET 1 readout as a positive. I think it may exude management's confident in successful COMET 1 readout. Not in Exel's nature not to hedge. This group has been fairly conservative with regards to cash on balance sheet to perform daily activities.

  • Reply to

    10.8 month OS based on NRE cohort

    by hbomb57108 Jul 30, 2014 8:04 AM
    hbomb57108 hbomb57108 Jul 30, 2014 8:53 AM Flag

    "what is NRE?"

    The NRE is the non randomized extension of the RDT. The original RDT design was based on RECIST responses upon randomization and didn't incorporate the bone scan phenomenon. The NRE extension was designed to allow continuous dosing to all prostate cancer patients without fear of being randomized off drug.

  • The NRE cohort differs significantly from early RDT. My posts are not going through, so I need to keep it brief.

  • Reply to

    10.8

    by erniewerner Jul 29, 2014 12:11 AM
    hbomb57108 hbomb57108 Jul 30, 2014 7:30 AM Flag

    From below, of 144 NRE patients, 93 of those patients had 100mg dose, while 51 had 40 mg dose.

    "Safety data for the NRE were presented at two medical meetings in 2012. At the ASCO Annual Meeting in June 2012, Dr. Matthew Smith of Massachusetts General Hospital presented data from 93 patients receiving a 100 mg daily dose of cabozantinib (Abstract #4513). At the European Society for Medical Oncology Congress in September 2012, Dr. Johann de Bono, of The Institute of Cancer Research, London, presented data from 51 patients receiving a 40 mg daily dose of cabozantinib (Abstract #897O). Across dose levels, the most common adverse events (AEs) of grade 3 or higher were fatigue, hypertension, and venous thrombosis. 25% of patients in the 40 mg dose cohort experienced one dose reduction due to an AE, and 84% of patients in the 100 mg dose cohort experienced at least one dose reduction due to an AE. Overall, the lower starting dose of 40 mg was better tolerated with lower rates of dose reduction and interruption."

  • Reply to

    10.8

    by erniewerner Jul 29, 2014 12:11 AM
    hbomb57108 hbomb57108 Jul 30, 2014 7:26 AM Flag

    "The differences follow: RDT had 46% chemo refractory and 10% Abi/MDV refractory patients. Comet has 100% chemo and 100% Abi/MDV refractory enrolment. RDT had 100% soft tissue mets and Comet will have about 1/3 with soft tissue mets. RDT had about 60% start dosage at 100mg/day and 40% at 40mg/day. Comet has all patients starting at 60mg/day."

    The 10.8 month survival benefit only included NRE cohort. Those characteristics were quite different than RDT by itself.

    Here are some of the nuggets

    -The interim results presented today comprise data from 144 men with mCRPC in the NRE cohort of an ongoing phase 2 randomized discontinuation trial.

    - 73% of patients had received two or more prior therapies including docetaxel and abiraterone, enzalutamide, and/or cabazitaxel

    -All patients had disease progression in either bone or soft tissue disease within 6 months of completion of docetaxel treatment, and the protocol differed from typical CRPC studies in that it excluded patients who progressed by PSA criteria alone, who generally have a better overall prognosis

    -All patients also had bone metastases on bone scan and 31% had measurable soft tissue disease.

    -In 36% of patients, disease progression was very rapid, occurring less than one month following the last dose of taxane therapy

EXEL
1.65+0.07(+4.76%)Oct 20 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Apple Inc.
NasdaqGSMon, Oct 20, 2014 4:00 PM EDT